Nkarta, Inc. (NKTX)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
3.47 USD
+0.67
(23.929%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 3.47 Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ★★☆☆☆ |
Hot Take | April 18, 2026, 10:32 p.m. EDT
Nkarta presents a high-conviction asymmetric setup driven by regulatory catalysts (FDA approvals, updated protocols) and crushing analyst consensus, but it is heavily weighted for a short-term momentum surge rather than a stable long-term hold. The stock is widely sold by insiders despite the 'Strong Buy' ratings, creating a dichotomy between fundamental safety and speculative pressure. While the balance sheet is pristine and the yield is zero due to current cash burn, the pure short-term directional evidence points to a high-probability move towards the $5.00 call cluster resistance. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.118582 |
| MSTL | 0.120766 |
| AutoTheta | 0.156137 |
| AutoARIMA | 0.639476 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.62 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.562 |
| Excess Kurtosis | -0.72 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 24.468 |
| Market Cap | 247,378,000 |
| Forward P/E | -1.94 |
| Beta | 0.67 |
| Website | https://www.nkartatx.com |
As of April 18, 2026, 10:32 p.m. EDT: Options data reveals a massive bullish asymmetry. Call Option-Open-Interest (OI) heavily concentrates at the $5.00 strike, acting as a significant upside barrier and gamma exposure point above the current price ($3.47), accounting for 75-88% of total OI in near-to-medium term expirations. Put activity is negligible (zero ITM puts for >50 days out), indicating no support at lower price levels. Implied Volatility is elevated (1.22 for long-term calls) compared to puts, suggesting traders anticipate higher upside moves or binary positive catalysts (regulatory/clinical) than downside risk.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.8756757 |
| Address1 | 1,150 Veterans Boulevard |
| All Time High | 79.16 |
| All Time Low | 1.28 |
| Ask | 3.53 |
| Ask Size | 5 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 918,670 |
| Average Daily Volume3 Month | 763,785 |
| Average Volume | 763,785 |
| Average Volume10Days | 918,670 |
| Beta | 0.669 |
| Bid | 3.34 |
| Bid Size | 5 |
| Board Risk | 7 |
| Book Value | 4.394 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.47 |
| Current Ratio | 12.688 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 3.485 |
| Day Low | 2.79 |
| Debt To Equity | 24.468 |
| Display Name | Nkarta |
| Earnings Timestamp | 1,774,468,800 |
| Earnings Timestamp End | 1,778,788,800 |
| Earnings Timestamp Start | 1,778,788,800 |
| Ebitda | -106,645,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.446 |
| Enterprise Value | 47,519,000 |
| Eps Current Year | -1.535 |
| Eps Forward | -1.79 |
| Eps Trailing Twelve Months | -1.41 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.3144 |
| Fifty Day Average Change | 1.1556001 |
| Fifty Day Average Change Percent | 0.4993087 |
| Fifty Two Week Change Percent | 87.567566 |
| Fifty Two Week High | 3.485 |
| Fifty Two Week High Change | -0.0149998665 |
| Fifty Two Week High Change Percent | -0.0043041226 |
| Fifty Two Week Low | 1.63 |
| Fifty Two Week Low Change | 1.84 |
| Fifty Two Week Low Change Percent | 1.1288344 |
| Fifty Two Week Range | 1.63 - 3.485 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,594,387,800,000 |
| Float Shares | 56,624,610 |
| Forward Eps | -1.79 |
| Forward P E | -1.9385475 |
| Free Cashflow | -53,593,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 108 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04956 |
| Held Percent Institutions | 0.77972 |
| Implied Shares Outstanding | 71,290,490 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-07-10 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. |
| Long Name | Nkarta, Inc. |
| Market | us_market |
| Market Cap | 247,378,000 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_544531597 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -104,084,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 247,378,000 |
| Number Of Analyst Opinions | 5 |
| Open | 2.835 |
| Operating Cashflow | -88,699,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 925 407 1049 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.47 |
| Post Market Time | 1,776,470,374 |
| Previous Close | 2.8 |
| Price Eps Current Year | -2.2605865 |
| Price Hint | 4 |
| Price To Book | 0.78971326 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.408 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.2 |
| Region | US |
| Regular Market Change | 0.67 |
| Regular Market Change Percent | 23.9286 |
| Regular Market Day High | 3.485 |
| Regular Market Day Low | 2.79 |
| Regular Market Day Range | 2.79 - 3.485 |
| Regular Market Open | 2.835 |
| Regular Market Previous Close | 2.8 |
| Regular Market Price | 3.47 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 3,136,442 |
| Return On Assets | -0.15991999 |
| Return On Equity | -0.289 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 5 |
| Shares Outstanding | 71,290,490 |
| Shares Percent Shares Out | 0.0776 |
| Shares Short | 5,531,075 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 5,857,300 |
| Short Name | Nkarta, Inc. |
| Short Percent Of Float | 0.1026 |
| Short Ratio | 8.41 |
| Source Interval | 15 |
| State | CA |
| Symbol | NKTX |
| Target High Price | 25.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 14.2 |
| Target Median Price | 11.0 |
| Total Cash | 276,279,008 |
| Total Cash Per Share | 3.875 |
| Total Debt | 76,420,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.41 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.11645 |
| Two Hundred Day Average Change | 1.35355 |
| Two Hundred Day Average Change Percent | 0.6395379 |
| Type Disp | Equity |
| Volume | 3,136,442 |
| Website | https://www.nkartatx.com |
| Zip | 94,080 |